Therefore, sGC stimulators might provide an adjunctive treatment modality for DMD patients rather than a stand-alone option, similar to current treatment regimens which include combinations like MR-antagonists with ACE-inhibitors [32]. This evidence concerns the gene SGCB and Duchenne muscular dystrophy.